Copenhagen Index versus ROMA in preoperative ovarian malignancy risk stratification: Result from the first Vietnamese prospective cohort study
- PMID: 33994145
- DOI: 10.1016/j.ygyno.2021.05.001
Copenhagen Index versus ROMA in preoperative ovarian malignancy risk stratification: Result from the first Vietnamese prospective cohort study
Abstract
Objectives: This study aimed to evaluate the diagnostic performances of the Copenhagen Index (CPH-I) and Risk of Ovarian Malignancy Algorithm (ROMA) in the preoperative prediction of ovarian cancer.
Methods: In a prospective cohort study, data were collected from 475 patients with ovarian masses diagnosed by gynecologic examination / ultrasound who were hospitalized at the Departments of Obstetrics and Gynecology, Hue University of Medicine and Pharmacy Hospital and Hue Central Hospital, Vietnam, between January 2018 and June 2020. ROMA and CPH-I were calculated based on measurements of serum carbohydrate antigen (CA-125) and human epididymis protein (HE4). The final diagnosis was based on clinical features, radiologic and histologic findings, and the International Federation of Gynecology and Obstetrics (FIGO) 2014 stages of ovarian cancer were recorded. Matching the values of ROMA and CPH-I to postoperative histopathology reports resulted in the preoperative prediction values.
Results: Among the 475 women, 408 had benign tumors, 5 had borderline tumors and 62 had malignant tumors. The two indices showed similar discriminatory performances with no significant differences (p > 0.05). At an optimal cut-off, the sensitivities/specificities of ROMA and CPH-I for ovarian cancer diagnosis were 74.2% and 91.8%, 87.1% and 78.5%, respectively. The optimal cut-off for CPH-I was 1.89%. The areas under the ROC curves (AUCs) of ROMA and CPH-I were 0.882 (95% CI: 0.849-0.909) and 0.898 (95% CI: 0.867-0.924), respectively.
Conclusions: The introduction of the Copenhagen Index to help stratify the malignancy risk of ovarian tumors, irrespective of menopausal status, might be applied as a simple alternative with a similar efficacy to ROMA in clinical practice.
Keywords: CA-125; Copenhagen index (CPH-I); HE4; Ovarian tumor; Risk of ovarian malignancy algorithm (ROMA).
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors have no conflicts of interest.
Similar articles
-
Diagnostic performances of the Ovarian Adnexal Reporting and Data System, the Risk of Ovarian Malignancy Algorithm, and the Copenhagen Index in the preoperative prediction of ovarian cancer: a prospective cohort study.J Gynecol Oncol. 2025 Mar;36(2):e30. doi: 10.3802/jgo.2025.36.e30. Epub 2024 Sep 24. J Gynecol Oncol. 2025. PMID: 39344149 Free PMC article.
-
A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer - An international multicenter study in women with an ovarian mass.Gynecol Oncol. 2015 Sep;138(3):640-6. doi: 10.1016/j.ygyno.2015.06.021. Epub 2015 Jun 16. Gynecol Oncol. 2015. PMID: 26086566
-
CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages.Dis Markers. 2019 Oct 13;2019:6241743. doi: 10.1155/2019/6241743. eCollection 2019. Dis Markers. 2019. PMID: 31737130 Free PMC article.
-
Standard and optimal cut-off values of serum ca-125, HE4 and ROMA in preoperative prediction of ovarian cancer in Vietnam.Gynecol Oncol Rep. 2018 Jul 18;25:110-114. doi: 10.1016/j.gore.2018.07.002. eCollection 2018 Aug. Gynecol Oncol Rep. 2018. PMID: 30109256 Free PMC article. Review.
-
[Ovarian tumor markers of presumed benign ovarian tumors].J Gynecol Obstet Biol Reprod (Paris). 2013 Dec;42(8):752-9. doi: 10.1016/j.jgyn.2013.09.030. Epub 2013 Nov 7. J Gynecol Obstet Biol Reprod (Paris). 2013. PMID: 24210243 Review. French.
Cited by
-
Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation Study.Cancers (Basel). 2022 Mar 31;14(7):1780. doi: 10.3390/cancers14071780. Cancers (Basel). 2022. PMID: 35406551 Free PMC article.
-
Molecular Biomarkers for the Early Detection of Ovarian Cancer.Int J Mol Sci. 2022 Oct 10;23(19):12041. doi: 10.3390/ijms231912041. Int J Mol Sci. 2022. PMID: 36233339 Free PMC article. Review.
-
The Comparison of Three Predictive Indexes to Discriminate Malignant Ovarian Tumors from Benign Ovarian Endometrioma: The Characteristics and Efficacy.Diagnostics (Basel). 2022 May 12;12(5):1212. doi: 10.3390/diagnostics12051212. Diagnostics (Basel). 2022. PMID: 35626367 Free PMC article.
-
Comparison of HE4, CA125, ROMA and CPH-I for Preoperative Assessment of Adnexal Tumors.Diagnostics (Basel). 2022 Jan 17;12(1):226. doi: 10.3390/diagnostics12010226. Diagnostics (Basel). 2022. PMID: 35054393 Free PMC article.
-
Diagnostic value of the Risk of Ovarian Malignancy Algorithm (ROMA) index in the detection of ovarian cancer in postmenopausal women: a systematic review and meta-analysis.BMC Womens Health. 2025 Jun 5;25(1):280. doi: 10.1186/s12905-025-03766-4. BMC Womens Health. 2025. PMID: 40474158 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous